Genedata said this week that its Selector software is being used by the Integrated Phenotype-Genotype project — a consortium of companies in the biotechnology industry — to analyze and manage data from production strains and processes in industrial biotechnology.
The IPG project aims to develop a platform for biotech strain and process development that integrates high-throughput phenotyping and genotyping and can identify complex genetic effects that influence biotechnologically relevant production phenotypes.
Genedata explained that the project platform is based on its Selector software and enables large-scale, cross-strain comparisons by systematically identifying mutation hotspots that pinpoint novel targets for de-bottlenecking as well as metabolic engineering of production strains. The platform uses parallelized, multiplexed phenotype assays to process, store, and mine large volumes of data.
In a statement, Stephan Hans, a senior scientist at consortium member Evonik Industries, noted that "correlating the productivity of our proprietary microbial production strains with their genotypes ... is extremely challenging, in particular matching the synergistic combinations of mutations against a high background of random mutations."
He explained that Selector meets this challenge by identifying "genomic changes and [isolating] non-beneficial or even detrimental mutations," which allows development groups to "identify hidden metabolic bottlenecks in our biotech production."
Separately, Genedata announced that Takeda Pharmaceutical has expanded its license for Genedata Expressionist.
Currently, Takeda uses the tool for managing and analyzing mass spectrometry data for both metabolomics and proteomics research and development.
With the expanded license, Takeda will have access to the latest release of Expressionist, which includes improvements in multi-vendor MS data integration, support for untargeted proteomics and metabolomics, and targeted multiple reaction monitoring.